Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma

Blood (2024) 144 (Supplement 1): 1993.

https://doi.org/10.1182/blood-2024-205614

Published: 2024

Journal Articles

RAMP up: Risk Adapted Post-Autologous Transplant Maintenance Therapy in MRD Positive Myeloma Patients

Karen Sweiss, Craig C. Hofmeister, Ghulam Rehman Mohyuddin, Amandeep Godara, Brian McClune, Damiano Rondelli, Danny Hadidi, David Chan, Matias Eugenio Sanchez, Min Hai, Mitch A. Phelps, Chukwuemeka Uzoka, Douglas Sborov

Blood (2023) 142 (Supplement 1): 4974.

https://doi.org/10.1182/blood-2023-191148

Published: 2023

Journal Articles

Effect of Predicted Fludarabine Lymphodepletion Exposure on Clinical Outcomes in Myeloma Patients Undergoing BCMA-CAR-T: An Exploratory Analysis from CARTITUDE-1

Blood (2022) 140 (Supplement 1): 4323–4324.

https://doi.org/10.1182/blood-2022-159501

Published: 2022

Journal Articles

Phase 1 Trial of AUC-Targeted Melphalan in Myeloma Patients Undergoing Autologous Transplant (The MyMel Study)

Karen Sweiss, Pritesh Patel, Janet Guo, Kyeongmin Kim, Kasey Hill, Nicole Abbott, Jeremy Johnson, Donald Irby, John G. Quigley, Damiano Rondelli, R Donald Harvey, Ajay K. Nooka, Madhav Dhodapkar, Jonathan L. Kaufman, Nisha S. Joseph, Sagar Lonial, Douglas W. Sborov, Mitch A Phelps, Craig C Hofmeister

Blood (2022) 140 (Supplement 1): 5988–5990.

https://doi.org/10.1182/blood-2022-170778

Published: 2022

Journal Articles

Comparison of Individualized Versus MAP-Bayesian Predicted AUC of Busulfan in FluBu4 Treated Patients Undergoing Allogeneic Transplant

Karen Sweiss, PharmD, Eric Wenzler, Hung H Nguyen, MLS, Avadhut D Joshi, PhD, Rosa Yeh, PharmD, Gregory Sampang Calip, PharmD,MPH,PhD, Jeremy Johnson, PharmD, PhD, Donald Irby, PhD, Mitch A. Phelps, PhD, Damiano Rondelli, MD, Pritesh Patel, MB, ChB

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-143430

Published: 2020

Journal Articles

ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL

Swagata Goswami, MSc, Chi-Ling Chiang, PhD, Kevan Zapolnik, BS, Zhiliang Xie, James L. Lee, PhD, Sivasubramanian Baskar, Christoph Rader, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Bhavana Bhatnagar, DO, Natarajan Muthusamy, DVM,PhD

Blood (2019) 134 (Supplement_1): 3798.

https://doi.org/10.1182/blood-2019-128828

Published: 2019

Journal Articles

ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model

Chi-Ling Chiang, Swagata Goswami, Frank W. Frissora, Zhiliang Xie, Pearlly S. Yan, Ralf Bundschuh, Logan A. Walker, Xiaomeng Huang, Rajeswaran Mani, Xiaokui M. Mo, Sivasubramanian Baskar, Christoph Rader, Mitch A. Phelps, Guido Marcucci, John C. Byrd, L. James Lee, Natarajan Muthusamy

Blood (2019) 134 (5): 432–444.

https://doi.org/10.1182/blood.2018882290

Published: 2019

Includes: Supplemental data

Journal Articles

Tumor Antigen ROR1 Targeted Delivery of MiR-29b in Chronic Lymphocytic Leukemia Induces Epigenetic Reprograming Resulting in Cell Cycle Arrest

Chi-Ling Chiang, MS, Swagata Goswami, MS, Rajeswaran Mani, DVM,PhD, Frank Frissora, MS, Zhiliang Xie, Xiaomeng Huang, PhD, Sivasubramanian Baskar, PhD, Christoph Rader, PhD, Mitch A. Phelps, PhD, Guido Marcucci, MD, John C. Byrd, MD, James L. Lee, PhD, Natarajan Muthusamy, DVM,PhD

Blood (2017) 130 (Supplement 1): 4981.

https://doi.org/10.1182/blood.V130.Suppl_1.4981.4981

Published: 2017

Journal Articles

OSU-2S, a Novel PKC Activator, Mediates PKC Dependent Cell Death, Differentiation and Cell Cycle Arrest in Acute Myeloid Leukemia

Swagata Goswami, MS, Rajeswaran Mani, DVM,PhD, Xiaokui Mo, PhD MAS, Pearlly S. Yan, PhD, Michael B Broe, PhD, Ralf Bundschuh, PhD, Larry State Beaver, Kevan Zapolnik, BS, Zhiliang Xie, Donna Bucci, David M. Lucas, PhD, Allison R. Walker, MD MPH, Alice S. Mims, MD MSCR, Rebecca B. Klisovic, MD, Ching-Shih Chen, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Sumithira Vasu, MDMBBS, Natarajan Muthusamy, DVM,PhD

Blood (2017) 130 (Supplement 1): 1247.

https://doi.org/10.1182/blood.V130.Suppl_1.1247.1247

Published: 2017

Journal Articles

Rituximab immunotherapy: it’s getting personal

Mitch A. Phelps

Blood (2017) 129 (19): 2595–2596.

https://doi.org/10.1182/blood-2017-03-772061

Published: 2017

Journal Articles

Phase 1 Evaluation of Oral Tetrahydrouridine-Decitabine As Non-Cytotoxic Epigenetic Disease Modification for Sickle Cell Disease

Robert E Molokie, MD, Donald Lavelle, PhD, Michel Gowhari, DO, Michael Pacini, PharmD, Lani Krauz, Johara Hassan, MD, Vinzon Ibanez, Maria A Ruiz, Daisy Pacelli, Sherry Fada, Mitch A. Phelps, PhD, Santosh L. Saraf, MD, Lewis L. Hsu, MD PhD, Victor R. Gordeuk, MD, Joseph DeSimone, PhD, Yogenthiran Saunthararajah, MD

Blood (2016) 128 (22): 124.

https://doi.org/10.1182/blood.V128.22.124.124

Published: 2016

Journal Articles

G-CSF Starting Day +1 after Autologous Transplant Is Safer Than Day +5 or Day +7 in Patients with Multiple Myeloma

Francesca Cottini, Douglas Sborov, Yu Kyoung Cho, Misty Lamprecht, Karen Tackett, Junan Li, Steven M. Devine, Ming Poi, Mitch A. Phelps, Craig C Hofmeister, MD MPH

Blood (2016) 128 (22): 5790.

https://doi.org/10.1182/blood.V128.22.5790.5790

Published: 2016

Journal Articles

CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia

Swagata Goswami, MS, Rajeswaran Mani, DVM PhD, Chi-Ling Chiang, MS, Frank W Frissora, M.S., Xiaokui Mo, PhD MAS, Zhiliang Xie, Donna Bucci, Amber Gordon, MLS, David M. Lucas, PhD, William Blum, MD, Alison R. Walker, MD MPH, Alice S. Mims, MD MSCR, Rebecca B Klisovic, MD, Ching-Shih Chen, PhD, Robert J Lee, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Sumithira Vasu, MBBS, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 2748.

https://doi.org/10.1182/blood.V128.22.2748.2748

Published: 2016

Journal Articles

Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia

Parvathi Ranganathan, Xueyan Yu, Ramasamy Santhanam, Jessica Hofstetter, Alison Walker, Katherine Walsh, Bhavana Bhatnagar, Rebecca Klisovic, Sumithira Vasu, Mitch A. Phelps, Steven Devine, Sharon Shacham, Michael Kauffman, Guido Marcucci, William Blum, Ramiro Garzon

Blood (2015) 125 (17): 2689–2692.

https://doi.org/10.1182/blood-2014-10-607648

Published: 2015

Includes: Supplemental data

Journal Articles

OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells

Ta-Ming Liu, Yonghua Ling, Jennifer A. Woyach, Kyle Beckwith, Yuh-Ying Yeh, Erin Hertlein, Xiaoli Zhang, Amy Lehman, Farrukh Awan, Jeffrey A. Jones, Leslie A. Andritsos, Kami Maddocks, Jessica MacMurray, Santosh B. Salunke, Ching-Shih Chen, Mitch A. Phelps, John C. Byrd, Amy J. Johnson

Blood (2015) 125 (2): 284–295.

https://doi.org/10.1182/blood-2014-06-583518

Published: 2015

Includes: Supplemental data

Journal Articles

Combination with Thu to Address Pharmacologic Limitations of Decitabine, Interim PK/PD from a Phase 1/2 Clinical Trial of Oral Thu-Decitabine in Sickle Cell Disease

Donald Lavelle, PhD, Michel Gowhari, DO, Michael Pacini, PharmD, Lani Krauz, RN, Johara Hassan, MD, Vinzon Ibanez, Maria A. Ruiz, MSc, Daisy Pacelli, BSc, Chaher Alhandalous, MD, Mitch A. Phelps, PhD, Kathleen Fenner, BS,MS, Reda Z. Mahfouz, MDPhD, John Barnard, Lewis L. Hsu, MD PhD, Victor R. Gordeuk, MD, Joseph DeSimone, PhD, Yogen Saunthararajah, MD, Robert E. Molokie, MD

Blood (2014) 124 (21): 90.

https://doi.org/10.1182/blood.V124.21.90.90

Published: 2014

Journal Articles

Development of a Predictive Pharmacokinetic and Pharmacodynamic Model to Personalize Melphalan Dosing in Autologous Transplant for Patients with Multiple Myeloma

Yu Kyoung Cho, MS, Junan Li, PhD, Douglas W. Sborov, MD, Jiang Wang, PhD, Yue Gao, PhD, Misty Lamprecht, CNS, Ming Poi, PharmD, PhD, Mitch A. Phelps, PhD, Craig C Hofmeister, MD MPH

Blood (2014) 124 (21): 1086.

https://doi.org/10.1182/blood.V124.21.1086.1086

Published: 2014

Journal Articles

A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Daniel A. Pollyea, MD MS, Steven Coutre, MD, Lia Gore, Nichole Adler, RN, BSN, Pamela Harris, MD, Mitch A. Phelps, PhD, Amy J. Johnson, PhD, YongHua Ling, Hao Li, Jonathan A Gutman, MD, John C. Byrd, MD

Blood (2014) 124 (21): 1987.

https://doi.org/10.1182/blood.V124.21.1987.1987

Published: 2014

Journal Articles

2-Hour Cryotherapy Effectively Reduces Severe Mucositis Associated with High-Dose Melphalan Followed By Stem Cell Rescue: Results from a Randomized Trial

Douglas W. Sborov, MD, Misty Lamprecht, CNS, Don Benson, MD PhD, Karen Tackett, RN, Yvonne A Efebera, MD, Rosko E Ashley, MD, Steven M. Devine, MD, Ming Poi, PharmD, PhD, Mitch A. Phelps, PhD, Craig C Hofmeister, MD MPH

Blood (2014) 124 (21): 3960.

https://doi.org/10.1182/blood.V124.21.3960.3960

Published: 2014

Journal Articles

A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2’-O-Methylphosphorothioate Mir-29b

Hongyan Wang, PhD, Ramasamy Santhanam, Ph.D, Zhiliang Xie, MD, Xiaomeng Huang, Ming Chiu, Mitch A. Phelps, PhD, Alison R Walker, MD, Michael A. Caligiuri, MD, Ramiro Garzon, MD, James Lee, PhD, Natarajan Muthusamy, DVM, Ph.D, Kenneth K. Chan, Ph.D, Guido Marcucci, MD

Blood (2013) 122 (21): 3933.

https://doi.org/10.1182/blood.V122.21.3933.3933

Published: 2013

NARROW

Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma

RAMP up: Risk Adapted Post-Autologous Transplant Maintenance Therapy in MRD Positive Myeloma Patients

Effect of Predicted Fludarabine Lymphodepletion Exposure on Clinical Outcomes in Myeloma Patients Undergoing BCMA-CAR-T: An Exploratory Analysis from CARTITUDE-1

Phase 1 Trial of AUC-Targeted Melphalan in Myeloma Patients Undergoing Autologous Transplant (The MyMel Study)

Comparison of Individualized Versus MAP-Bayesian Predicted AUC of Busulfan in FluBu4 Treated Patients Undergoing Allogeneic Transplant

ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL

ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model

Tumor Antigen ROR1 Targeted Delivery of MiR-29b in Chronic Lymphocytic Leukemia Induces Epigenetic Reprograming Resulting in Cell Cycle Arrest

OSU-2S, a Novel PKC Activator, Mediates PKC Dependent Cell Death, Differentiation and Cell Cycle Arrest in Acute Myeloid Leukemia

Rituximab immunotherapy: it’s getting personal

Phase 1 Evaluation of Oral Tetrahydrouridine-Decitabine As Non-Cytotoxic Epigenetic Disease Modification for Sickle Cell Disease

G-CSF Starting Day +1 after Autologous Transplant Is Safer Than Day +5 or Day +7 in Patients with Multiple Myeloma

CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia

Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia

OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells

Combination with Thu to Address Pharmacologic Limitations of Decitabine, Interim PK/PD from a Phase 1/2 Clinical Trial of Oral Thu-Decitabine in Sickle Cell Disease

Development of a Predictive Pharmacokinetic and Pharmacodynamic Model to Personalize Melphalan Dosing in Autologous Transplant for Patients with Multiple Myeloma

A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

2-Hour Cryotherapy Effectively Reduces Severe Mucositis Associated with High-Dose Melphalan Followed By Stem Cell Rescue: Results from a Randomized Trial

A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2’-O-Methylphosphorothioate Mir-29b

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only